Skip to content

Released Nov 5, 2020, after the close

10-Q filed Nov 9, 2020, 40 days after period end · 0001162194-20-000107

Q3 2020 · 10-Q
Revenue$39.86M+50.4% vs Q3 2019+53.0% vs Q2 2020
Net Income-$6.00MN/M vs Q3 2019N/M vs Q2 2020
EPS Diluted-$0.08N/M vs Q3 2019N/M vs Q2 2020
Gross Profit$20,799,000+50.3%
Operating Income-$5,464,000N/M
Operating Cash Flowderived-$4,599,000N/M
Free Cash Flowderived-$4,938,000N/M
Margins · derived
Gross margin52.2%−0.0 pt vs Q3 2019
Operating margin-13.7%+38.4 pt vs Q3 2019
Net margin-15.0%+33.6 pt vs Q3 2019

What the release said

The release

Same quarter

MetricQ3 2020Q3 2019Q3 2018Q3 2017
Revenue$39.86M$26.50M$28.96M$24.75M
Net Income-$6.00M-$12.89M-$14.75M-$15.94M
EPS Diluted-$0.08-$0.19-$0.38-$0.46

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR